Delayed administration of filgrastim (G-CSF) following autologous peripheral blood stem cell transplantation (APBSCT) in pediatric patients does not change time to neutrophil engraftment and reduces use of G-CSF
- PMID: 20063422
- DOI: 10.1002/pbc.22394
Delayed administration of filgrastim (G-CSF) following autologous peripheral blood stem cell transplantation (APBSCT) in pediatric patients does not change time to neutrophil engraftment and reduces use of G-CSF
Abstract
Background: Delayed initiation of granulocyte colony stimulating factor (G-CSF) after high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell (APBSCT) in adult patients does not affect time to neutrophil or platelet engraftment, duration of fever, incidence of bacteremia, duration of non-prophylactic antibiotic therapy, and length of hospitalization when compared to early initiation. This study compares the effect of delayed (day +6) versus early (day +1) administration of G-CSF in pediatric patients on time to neutrophil engraftment (TNE), duration and cost of G-CSF therapy, incidence of blood stream infections, duration of febrile-neutropenia, duration of non-prophylactic antibiotic therapy, and duration of hospitalization due to febrile-neutropenia.
Methods: This is a retrospective review of 65 patients who engrafted after receiving APBSCT and G-CSF between 1993 and 2006. They were divided into the delayed group (day +6) (n = 46) and the early group (day +1) (n = 19).
Results: The median ages were 4.7 and 5.3 years in the early and delayed groups, respectively. There was no significant difference in TNE (P = 0.06) between the two groups. The duration of G-CSF administration was significantly less in the delayed group (P = 0.003). No significant differences were observed in the duration of neutropenia, time to platelet engraftment, the incidence of blood stream infections, and duration of fevers. Duration of hospitalization due to febrile-neutropenia was significantly lower in the delayed group (P = 0.01). Significant cost savings were observed by delaying G-CSF administration.
Conclusion: Delayed administration of G-CSF after APBSCT in children has no adverse effect on TNE or other clinical outcomes when compared to early administration and may incur substantial cost savings.
Similar articles
-
A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation.Bone Marrow Transplant. 1998 Nov;22(10):965-9. doi: 10.1038/sj.bmt.1701469. Bone Marrow Transplant. 1998. PMID: 9849693 Clinical Trial.
-
CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.Eur J Haematol. 2007 Feb;78(2):111-6. doi: 10.1111/j.1600-0609.2006.00793.x. Eur J Haematol. 2007. PMID: 17313558 Clinical Trial.
-
Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.Clin Ther. 2009;31 Pt 2:2388-95. doi: 10.1016/j.clinthera.2009.11.013. Clin Ther. 2009. PMID: 20110048
-
Review and revision of clinical practice of using G-CSF after autologous and allogeneic hematopoietic stem cell transplantation at UCSD.J Oncol Pharm Pract. 2011 Jun;17(2):85-90. doi: 10.1177/1078155209354932. Epub 2009 Dec 16. J Oncol Pharm Pract. 2011. PMID: 20015929 Review.
-
Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia.Drugs. 1994 Nov;48(5):731-60. doi: 10.2165/00003495-199448050-00007. Drugs. 1994. PMID: 7530630 Review.
Cited by
-
Analysis of the feasibility of early hospital discharge after autologous hematopoietic stem cell transplantation and the implications to nursing care.Rev Bras Hematol Hemoter. 2014 Jul-Aug;36(4):264-8. doi: 10.1016/j.bjhh.2014.05.003. Epub 2014 May 29. Rev Bras Hematol Hemoter. 2014. PMID: 25031165 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources